Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Australia
  4. Australian Stock Exchange
  5. Rhinomed Limited
  6. News
  7. Summary
    RNO   AU000000RNO1

RHINOMED LIMITED

(RNO)
End-of-day quote. End-of-day quote Australian Stock Exchange - 11/29
0.255 AUD   -5.56%
11/18RHINOMED : CEO presentation to 2021 AGM
PU
11/10Investor update November 2021
PU
10/26Rhinomed Secures Ethics Approval for Post-Market Trial of Nasal Swab Product
MT
SummaryChartsNewsCalendarCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Rhinomed Limited Announces Ethics Approval Granted for Clinical Trial of First Nasal Swab Designed Specifically for Children

08/26/2021 | 07:36pm EST

Rhinomed Limited has completed development of the world's first nasal swab designed specifically for children. The Rhinoswab Junior has been designed to deliver all the benefits of the existing Rhinoswab but with several novel features that reduce the fear, anxiety and trauma associated with the use of existing standard of care nasal swabs. The company has received Human Research Ethics Committee approval to commence a clinical trial of the Rhinoswab Junior at The Royal Children's Hospital Melbourne. The trial, known as The Diagnosis of Respiratory Disease in Children with Rhinoswab Study will investigate the diagnosis of respiratory viruses in children with Rhinoswab Junior, which is designed to collect a nasal sample from children without the discomfort and distress often associated with the combined throat and deep nasal swabs. Rhinoswab Junior is a smaller version of the Rhinoswab device with child friendly features to engage children in the sampling process. Rhinoswab's design also allows for standardisation of the site of biological sampling, as compared with CTDN swabs, which are operator dependent. Specifically, the diagnostic validation study will evaluate the Rhinoswab, a self-collection anterior nasal swab, as an alternative method to combined throat and deep nasal swab for respiratory sample collection in children aged 4-18 years at The Royal Children's Hospital. The objectives of the study are to investigate: The laboratory test performance of the Rhinoswab compared with the current standard of care CTDN swab; The comfort and preference of Rhinoswab compared to the CTDN swab; If laboratory handling of Rhinoswab is equivalent to the CTDN swab. The study will aim to recruit 250 children at the Respiratory Infection Clinic at the RCH for a SARS-CoV-2 test. The CTDN sample will be collected by a healthcare worker; however, children will self collect the Rhinoswab sample under the supervision of a healthcare worker. The study will also recruit up to 10 staff to evaluate Rhinoswab against laboratory handling, process and workflow requirements.


ę S&P Capital IQ 2021
All news about RHINOMED LIMITED
11/18RHINOMED : CEO presentation to 2021 AGM
PU
11/10Investor update November 2021
PU
10/26Rhinomed Secures Ethics Approval for Post-Market Trial of Nasal Swab Product
MT
10/26Rhinoswab Clinical Trial Approves At St Vincent's Hospital
CI
10/19RHINOMED : New swab takes away children's fear of swabbing
EQ
09/28Rhinomed Limited Auditor Raises 'Going Concern' Doubt
CI
09/13Rhinomed Limited Appoints Rhinoswab Distributors for Australia and Belgium, the Netherl..
CI
09/10RHINOMED : to Deliver One Million COVID-19 Nasal Swabs to Australia's Victoria Government
MT
09/09Rhinomed Limited Receives an Initial Purchase Order for One Million Rhinoswabs from the..
CI
08/26Rhinomed Limited Announces Ethics Approval Granted for Clinical Trial of First Nasal Sw..
CI
More news
Financials
Sales 2021 4,42 M 3,16 M 3,16 M
Net income 2021 -8,64 M -6,17 M -6,17 M
Net cash 2021 1,87 M 1,34 M 1,34 M
P/E ratio 2021 -4,55x
Yield 2021 -
Capitalization 64,7 M 46,1 M 46,2 M
EV / Sales 2020 2,37x
EV / Sales 2021 8,48x
Nbr of Employees -
Free-Float 10,1%
Chart RHINOMED LIMITED
Duration : Period :
Rhinomed Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends RHINOMED LIMITED
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Managers and Directors
Michael Johnson Chief Executive Officer, MD & Executive Director
Sean Slattery Chief Financial Officer & Secretary
Ronald R. Dewhurst Non-Executive Chairman
Brent J. Scrimshaw Independent Non-Executive Director
Eric Knight Independent Non-Executive Director
Sector and Competitors